Press release
Bronchopulmonary Dysplasia Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Bronchopulmonary Dysplasia Clinical Trials
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more about our innovative pipeline today! @ Bronchopulmonary Dysplasia Pipeline Outlook - https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
• In September 2024:- EXO Biologics S.A.- Phase I Single Arm, Dose Escalating and Phase II Double Blind, Randomized, Placebo-controlled, Dose Finding Clinical Trial Assessing Safety and Efficacy of Intratracheal Administration of Allogeneic Umbilical Cord Mesenchymal Cells-derived Extracellular Vesicles in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns.
• DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
• The leading Bronchopulmonary Dysplasia Companies such as MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
• Promising Bronchopulmonary Dysplasia Therapies such as Sildenafil, PNEUMOSTEM, OHB-607, and others.
Stay informed about the cutting-edge advancements in Bronchopulmonary Dysplasia Treatments. Download for updates and be a part of the revolution in cancer care @ Bronchopulmonary Dysplasia Clinical Trials Assessment - https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bronchopulmonary Dysplasia Emerging Drugs Profile
• PNEUMOSTEM: MEDIPOST Co., Ltd.
PNEUMOSTEM Registered an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia (BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM Registered has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM Registered .
• AT-100: Airway Therapeutics
AT-100 is a novel recombinant human protein rhSP-D, an engineered version of an endogenous protein that reduces inflammation and infection in the body while modulating the immune response to break the cycle of injury and inflammation. Airway is focused on advancing AT-100 for the prevention of BPD in very preterm born babies and as a therapeutic for seriously ill COVID-19 patients. AT-100's anti-inflammatory and anti-infective properties also make it a potential treatment for other respiratory diseases such as influenza, respiratory syncytial virus (RSV) and inflammatory diseases outside the lung. The FDA and European Medicines Agency have granted AT-100 Orphan Drug Designation.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities in our groundbreaking Inter Bronchopulmonary Dysplasia Research and development projects @ Bronchopulmonary Dysplasia Unmet Needs - https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Discover the latest advancements in Bronchopulmonary Dysplasia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives - https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Bronchopulmonary Dysplasia Pipeline Report
• Coverage- Global
• Bronchopulmonary Dysplasia Companies- MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
• Bronchopulmonary Dysplasia Therapies- Sildenafil, PNEUMOSTEM, OHB-607, and others.
• Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ Bronchopulmonary Dysplasia Drugs and Companies - https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
• Introduction
• Executive Summary
• Bronchopulmonary Dysplasia: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Bronchopulmonary Dysplasia - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• Drug name: Company name
• Drug profiles in the detailed report.....
• Mid Stage Products (Phase II)
• PNEUMOSTEM: MEDIPOST Co., Ltd.
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I)
• AT-100: Airway Therapeutics
• Drug profiles in the detailed report.....
• Preclinical and Discovery Stage Products
• AVR 48: AyuVis Research
• Drug profiles in the detailed report.....
• Inactive Products
• Bronchopulmonary Dysplasia Key Companies
• Bronchopulmonary Dysplasia Key Products
• Bronchopulmonary Dysplasia- Unmet Needs
• Bronchopulmonary Dysplasia- Market Drivers and Barriers
• Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
• Bronchopulmonary Dysplasia Analyst Views
• Bronchopulmonary Dysplasia Key Companies
• Appendix
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/cardiorenal-syndrome-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Insomnia Market: https://www.delveinsight.com/report-store/insomnia-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Colorectal Cancer Crc Market: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Diabetic Nephropathy Market: https://www.delveinsight.com/report-store/diabetic-nephropathy-market
• Endoscopy Fluid Management Systems Market: https://www.delveinsight.com/blog/endoscopy-fluid-management-systems-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Prader-willi Syndrome Market: https://www.delveinsight.com/report-store/prader-willi-syndrome-market
• Spasticity Market: https://www.delveinsight.com/report-store/muscle-spasticity-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Acute Lung Injury Market: https://www.delveinsight.com/report-store/acute-lung-injury-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Angioedema Market: https://www.delveinsight.com/report-store/hereditary-angioedema-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3782163 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Bronchopulmonary
Bronchopulmonary Dysplasia (BPD) Patient Pool Analysis and Market Forecast 2024- …
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants requiring prolonged mechanical ventilation or supplemental oxygen. It remains one of the most serious complications of preterm birth, with lasting effects on pulmonary function, growth, and neurodevelopment.
The condition not only drives neonatal intensive care unit (NICU) costs but also increases long-term healthcare utilization for affected children. Growing global rates of preterm birth, along with improvements in neonatal…
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis
Bronchopulmonary Dysplasia (BPD) represents one of the most significant complications of preterm birth, affecting the respiratory system of premature infants and creating substantial healthcare challenges worldwide. The BPD epidemiology market encompasses therapeutic interventions, diagnostic tools, and supportive care technologies designed to address this chronic lung disease affecting neonates. As medical advances continue to improve survival rates among extremely premature infants, the prevalence of BPD has correspondingly increased, driving demand for…
Bronchopulmonary Dysplasia Treatment Market Growth Projections and Trends (2023- …
Bronchopulmonary Dysplasia (BPD) Treatment Market
Global Bronchopulmonary Dysplasia Treatment Market Overview
The global bronchopulmonary dysplasia (BPD) treatment market is poised for significant growth in the coming years. The market was valued at USD X billion in 2023 and is expected to reach USD Y billion by 2030, expanding at a CAGR of Z% from 2024 to 2030. With advancements in neonatal care and increasing awareness about BPD treatment options, the demand for…
Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more…
Bronchopulmonary Dysplasia Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Bronchopulmonary Dysplasia Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
BDP Market Size And Scope
The global BDP (Butane Diol Propylene) market is witnessing steady growth, fueled by its diverse applications in industries such as…
Bronchopulmonary Dysplasia Market to Reach US$ 445.6 Million by 2034
Market Overview:
The bronchopulmonary dysplasia market reached a value of US$ 269.3 Million in 2023 and expected to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.
The report offers a comprehensive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,…
